Page 1

lli Bristol Myers Squibb ™ ● ● ● Bristol Myers Squibb Reports Second Quarter Financial Results for 2021 Reports Second Quarter Revenues of $ 11.7 Billion , an Increase of 16 % YoY , or 13 % When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $ 0.47 and Non - GAAP EPS of $ 1.93 Delivers Strong Commercial Performance , Including Opdivo's Return to Growth and Momentum across New Product Portfolio Achieves Significant Regulatory and Clinical Milestones across Product Pipeline Further Strengthens Pipeline through Disciplined Business Development Agreements , including with Agenus and Eisai Adjusts GAAP and Reaffirms Non - GAAP EPS Guidance for 2021 ( NEW YORK , July 28 , 2021 ) - Bristol Myers Squibb ( NYSE : BMY ) today reports results for the second quarter of 2021 , which reflect robust product sales , continued advancement of the pipeline and strong clinical and operational performance across the company . " We delivered a strong quarter across each of our four therapeutic areas , including building momentum for our new product portfolio and Opdivo returning to growth , " said Giovanni Caforio , M.D. , board chair and chief executive officer , Bristol Myers Squibb . " We achieved significant clinical and regulatory milestones reflecting the hard work and dedication of our team , who together have built a portfolio of best - in - class medicines to meet the needs of patients with serious diseases . As we move forward , we remain focused on driving inline product performance , progressing our new launches , and advancing pipeline opportunities . Our robust and diverse pipeline combined with our clinical and commercial execution strengthen our confidence in our ability to renew the portfolio and achieve sustained growth . " $ amounts in millions , except per share amounts Total Revenues Earnings ( Loss ) Per Share GAAP Earnings Per Share - Non - GAAP 1 - Second Quarter 2021 $ 11,703 0.47 1.93 2020 $ 10,129 ( 0.04 ) 1.63 Change 16 % N / A 18 %